Literature DB >> 12671048

Normal levels of anticoagulant heparan sulfate are not essential for normal hemostasis.

Sassan HajMohammadi1, Keiichi Enjyoji, Marc Princivalle, Patricia Christi, Miroslav Lech, David Beeler, Helen Rayburn, John J Schwartz, Samad Barzegar, Ariane I de Agostini, Mark J Post, Robert D Rosenberg, Nicholas W Shworak.   

Abstract

Endothelial cell production of anticoagulant heparan sulfate (HS(act)) is controlled by the Hs3st1 gene, which encodes the rate-limiting enzyme heparan sulfate 3-O-sulfotransferase-1 (3-OST-1). In vitro, HS(act) dramatically enhances the neutralization of coagulation proteases by antithrombin. The in vivo role of HS(act) was evaluated by generating Hs3st1(-/-) knockout mice. Hs3st1(-/-) animals were devoid of 3-OST-1 enzyme activity in plasma and tissue extracts. Nulls showed dramatic reductions in tissue levels of HS(act) but maintained wild-type levels of tissue fibrin accumulation under both normoxic and hypoxic conditions. Given that vascular HS(act) predominantly occurs in the subendothelial matrix, mice were subjected to a carotid artery injury assay in which ferric chloride administration induces de-endothelialization and occlusive thrombosis. Hs3st1(-/-) and Hs3st1(+/+) mice yielded indistinguishable occlusion times and comparable levels of thrombin.antithrombin complexes. Thus, Hs3st1(-/-) mice did not show an obvious procoagulant phenotype. Instead, Hs3st1(-/-) mice exhibited genetic background-specific lethality and intrauterine growth retardation, without evidence of a gross coagulopathy. Our results demonstrate that the 3-OST-1 enzyme produces the majority of tissue HS(act). Surprisingly, this bulk of HS(act) is not essential for normal hemostasis in mice. Instead, 3-OST-1-deficient mice exhibited unanticipated phenotypes suggesting that HS(act) or additional 3-OST-1-derived structures may serve alternate biologic roles.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12671048      PMCID: PMC152578          DOI: 10.1172/JCI15809

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  49 in total

Review 1.  Thrombophilia and fetal growth restriction.

Authors:  L L Peeters
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2001-04       Impact factor: 2.435

2.  Anticoagulant heparan sulfate proteoglycans expression in the rat ovary peaks in preovulatory granulosa cells.

Authors:  M Princivalle; S Hasan; G Hosseini; A I de Agostini
Journal:  Glycobiology       Date:  2001-03       Impact factor: 4.313

3.  Effects of chronic reduction in uterine blood flow on fetal and placental growth in the sheep.

Authors:  U Lang; R S Baker; J Khoury; K E Clark
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2000-07       Impact factor: 3.619

Review 4.  Molecular diversity of heparan sulfate.

Authors:  J D Esko; U Lindahl
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

Review 5.  Heparan sulfate proteoglycans: intricate molecules with intriguing functions.

Authors:  R V Iozzo
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

6.  Increased thrombogenesis and embolus formation in mice lacking glycoprotein V.

Authors:  H Ni; V Ramakrishnan; Z M Ruggeri; J M Papalia; D R Phillips; D D Wagner
Journal:  Blood       Date:  2001-07-15       Impact factor: 22.113

7.  The effect of precursor structures on the action of glucosaminyl 3-O-sulfotransferase-1 and the biosynthesis of anticoagulant heparan sulfate.

Authors:  L Zhang; R Lawrence; J J Schwartz; X Bai; G Wei; J D Esko; R D Rosenberg
Journal:  J Biol Chem       Date:  2001-05-24       Impact factor: 5.157

Review 8.  Anticoagulant proteins in childhood venous and arterial thrombosis: a review.

Authors:  G B Segel; C A Francis
Journal:  Blood Cells Mol Dis       Date:  2000-10       Impact factor: 3.039

9.  A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry.

Authors:  D Shukla; J Liu; P Blaiklock; N W Shworak; X Bai; J D Esko; G H Cohen; R J Eisenberg; R D Rosenberg; P G Spear
Journal:  Cell       Date:  1999-10-01       Impact factor: 41.582

10.  Complete antithrombin deficiency in mice results in embryonic lethality.

Authors:  K Ishiguro; T Kojima; K Kadomatsu; Y Nakayama; A Takagi; M Suzuki; N Takeda; M Ito; K Yamamoto; T Matsushita; K Kusugami; T Muramatsu; H Saito
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

View more
  55 in total

Review 1.  Heparan sulfate: antithrombotic or not?

Authors:  Jeffrey I Weitz
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

Review 2.  Sulfation pattern in glycosaminoglycan: does it have a code?

Authors:  Hiroko Habuchi; Osami Habuchi; Koji Kimata
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

3.  Screening for anticoagulant heparan sulfate octasaccharides and fine structure characterization using tandem mass spectrometry.

Authors:  Hicham Naimy; Nancy Leymarie; Joseph Zaia
Journal:  Biochemistry       Date:  2010-05-04       Impact factor: 3.162

4.  Differential roles for 3-OSTs in the regulation of cilia length and motility.

Authors:  Judith M Neugebauer; Adam B Cadwallader; Jeffrey D Amack; Brent W Bisgrove; H Joseph Yost
Journal:  Development       Date:  2013-08-14       Impact factor: 6.868

5.  Expression and functional characterization of two natural heparin-binding site variants of antithrombin.

Authors:  P Dinarvand; L Yang; B O Villoutreix; A R Rezaie
Journal:  J Thromb Haemost       Date:  2018-01-08       Impact factor: 5.824

6.  Modification degrees at specific sites on heparan sulphate: an approach to measure chemical modifications on biological molecules with stable isotope labelling.

Authors:  Zhengliang L Wu; Miroslaw Lech
Journal:  Biochem J       Date:  2005-07-15       Impact factor: 3.857

Review 7.  Mice deficient in heparan sulfate 3-O-sulfotransferase-1: normal hemostasis with unexpected perinatal phenotypes.

Authors:  Nicholas W Shworak; Sassan HajMohammadi; Ariane I de Agostini; Robert D Rosenberg
Journal:  Glycoconj J       Date:  2002 May-Jun       Impact factor: 2.916

8.  Heparan sulfate 6-O-sulfotransferase isoform-dependent regulatory effects of heparin on the activities of various proteases in mast cells and the biosynthesis of 6-O-sulfated heparin.

Authors:  Md Ferdous Anower-E-Khuda; Hiroko Habuchi; Naoko Nagai; Osami Habuchi; Takashi Yokochi; Koji Kimata
Journal:  J Biol Chem       Date:  2012-12-06       Impact factor: 5.157

9.  Human follicular fluid heparan sulfate contains abundant 3-O-sulfated chains with anticoagulant activity.

Authors:  Ariane I de Agostini; Ji-Cui Dong; Corinne de Vantéry Arrighi; Marie-Andrée Ramus; Isabelle Dentand-Quadri; Sébastien Thalmann; Patricia Ventura; Victoria Ibecheole; Felicia Monge; Anne-Marie Fischer; Sassan HajMohammadi; Nicholas W Shworak; Lijuan Zhang; Zhenqing Zhang; Robert J Linhardt
Journal:  J Biol Chem       Date:  2008-07-31       Impact factor: 5.157

10.  N-sulfation of heparan sulfate regulates early branching events in the developing mammary gland.

Authors:  Kevin T Bush; Brett E Crawford; Omai B Garner; Kabir B Nigam; Jeffrey D Esko; Sanjay K Nigam
Journal:  J Biol Chem       Date:  2012-10-11       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.